About HistoRx
HistoRx is a company based in Branford (United States) founded in 2001 was acquired by Genoptix in September 2012. HistoRx has raised $13.26 million across 5 funding rounds from investors including HHS, Maven Capital Partners and Genoptix. HistoRx operates in a competitive market with competitors including Cellply, Lucid Scientific, Kiyatec, CytoTronics and Saguaro, among others.
- Headquarter Branford, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of HistoRx
HistoRx has successfully raised a total of $13.26M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $2.6 million completed in May 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in HistoRx
HistoRx has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Maven Capital Partners and Genoptix.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are targeted for private equity investments.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Corporate-backed venture capital firm focused on the healthcare sector
|
Locked | Locked | Locked |
Investor details for HistoRx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by HistoRx
Investment portfolio details for HistoRx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - HistoRx
Detailed financials for HistoRx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Historx Comparisons
Peer comparison for HistoRx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of HistoRx
HistoRx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cellply, Lucid Scientific, Kiyatec, CytoTronics and Saguaro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of in-vitro diagnostic products for the detection of cancer
|
|
| Locked | Locked | Locked |
Real-time cell analyzers are developed for oxygen consumption monitoring.
|
|
| Locked | Locked | Locked |
Kiyatec is focused on revolutionizing cancer care through predictive platforms.
|
|
| Locked | Locked | Locked |
Cell-based assays for drug discovery are developed via CMOS platform.
|
|
| Locked | Locked | Locked |
3D cell culture products are developed for drug discovery applications.
|
|
| Locked | Locked | Locked |
Metastatic cancer properties are targeted by Remedy Plan's containment therapy.
|
Detailed competitors of HistoRx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Historx
Complete news archive for HistoRx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about HistoRx
HistoRx was founded in 2001 and raised its 1st funding round 3 years after it was founded.
HistoRx is headquartered in Branford, United States. It is registered at Branford, Connecticut, United States.
HistoRx is a funded company, having raised a total of $13.26M across 5 funding rounds to date.
HistoRx was founded in 2001 in Branford, United States, focusing on tissue-based diagnostics in the pathology sector. Proprietary AQUA technology is utilized to analyze protein locations and quantities in cell sub-compartments while preserving spatial relationships in tissue samples and microarrays. Operations target research and clinical applications. The company was acquired by Genoptix, a Novartis subsidiary, in 2012.
HistoRx's top competitors include CytoTronics, Kiyatec and Remedy Plan.
HistoRx has 7 investors. Key investors include HHS, Maven Capital Partners, Genoptix, Brook Venture Partners, and Navigator Technology Ventures.